Xiuyan Wang

Active 2000–2025

72
Papers
18,181
Citations
44
h-index
63
i10-index

Citations

Citations per year for Xiuyan Wang1991: 2 citations1992: 1 citations1994: 1 citations1997: 1 citations2000: 2 citations2001: 15 citations2002: 34 citations2003: 40 citations2004: 58 citations2005: 41 citations2006: 70 citations2007: 44 citations2008: 43 citations2009: 63 citations2010: 50 citations2011: 40 citations2012: 59 citations2013: 136 citations2014: 129 citations2015: 196 citations2016: 229 citations2017: 254 citations2018: 339 citations2019: 839 citations2020: 1,086 citations2021: 1,052 citations2022: 893 citations2023: 791 citations2024: 1,210 citations2025: 578 citations2026: 23 citations1993: no citations, so this year is not shown1995–1996: no citations, so these years are not shown1998–1999: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,988 citing papers, 33.4% of this breakdownChina: 1,534 citing papers, 17.2% of this breakdownGermany: 552 citing papers, 6.2% of this breakdownUnited Kingdom: 403 citing papers, 4.5% of this breakdownItaly: 283 citing papers, 3.2% of this breakdownFrance: 268 citing papers, 3% of this breakdownCanada: 225 citing papers, 2.5% of this breakdownSpain: 219 citing papers, 2.5% of this breakdownAustralia: 187 citing papers, 2.1% of this breakdownNetherlands: 174 citing papers, 1.9% of this breakdownJapan: 171 citing papers, 1.9% of this breakdownIndia: 155 citing papers, 1.7% of this breakdown
0%33.4%Other 19.9%

Fields

  • Medicine78.4%
  • Biochemistry, Genetics and Molecular Biology8.5%
  • Immunology and Microbiology7.3%
  • Engineering2.4%
  • Agricultural and Biological Sciences0.6%
  • Materials Science0.5%
  • Other2.3%

Topics

  • CAR-T cell therapy research21.6%
  • Virus-based gene therapy research6.2%
  • Immune Cell Function and Interaction5.4%
  • Nanowire Synthesis and Applications4.8%
  • Immunotherapy and Immune Responses3.8%
  • Viral Infectious Diseases and Gene Expression in Insects3.7%
  • Other54.5%

Coauthors

All papers

Open in search
  1. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

    Authors: , , , , , , , , , , , , , , - New England Journal of Medicine 2018 cited by 2,675

  2. A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2021 cited by 560

  3. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michel Sadelain, Renier J. Brentjens - Science Translational Medicine 2014 cited by 2,497

  4. GPRC5D-Targeted CAR T Cells for Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ahmet Doǧan, Ola Landgren, Sergio Giralt, Jae H. Park, Saad Z. Usmani, Isabelle Rivière, Renier J. Brentjens, Eric L. Smith - New England Journal of Medicine 2022 cited by 384

  5. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs

    Authors: , , , , , , , , , , , , - Drug Resistance Updates 2023 cited by 278

  6. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape

    Authors: , , , , , , , , , , , , , , , , - Nature 2019 cited by 665

  7. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2018 cited by 924

  8. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Science Translational Medicine 2013 cited by 2,077

  9. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Science Translational Medicine 2019 cited by 385

  10. Clinical manufacturing of CAR T cells: foundation of a promising therapy

    Authors: , - Molecular Therapy — Oncolytics 2016 cited by 629

  11. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2011 cited by 1,284

  12. Cooperative CAR targeting to selectively eliminate AML and minimize escape

    Authors: , , , , , , , , , , , , , - Cancer Cell 2023 cited by 107

  13. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2019 cited by 279

  14. Cable vibration measurement based on broad-band phase-based motion magnification and line tracking algorithm

    Authors: , , , , , - Mechanical Systems and Signal Processing 2023 cited by 87

  15. Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells

    Authors: , , , , , , , , , , , , , , , , , , - Nature Biomedical Engineering 2022 cited by 71

  16. Quercetin reversed MDR in breast cancer cells through down‐regulating P‐gp expression and eliminating cancer stem cells mediated by YB‐1 nuclear translocation

    Authors: , , , , , - Phytotherapy Research 2018 cited by 127

  17. Low-density lipoprotein cholesterol and risk of intracerebral hemorrhage

    Authors: , , , , , , , , - Neurology 2019 cited by 194

  18. The Interferon-Inducible Protein Viperin Inhibits Influenza Virus Release by Perturbing Lipid Rafts

    Authors: , , - Cell Host & Microbe 2007 cited by 486

  19. Quercetin enhances chemotherapeutic effect of doxorubicin against human breast cancer cells while reducing toxic side effects of it

    Authors: , , , , , - Biomedicine & Pharmacotherapy 2018 cited by 161

  20. BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy

    Authors: , , , , , , , , , , , , , , , - Cancer Immunology Research 2019 cited by 94

  21. Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Isabelle Rivière, Michel Sadelain - Nature Medicine 2022 cited by 47

  22. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL

    Authors: , , , , , , , , , , , , , , - JCI Insight 2019 cited by 99

  23. Anticancer effects of miR-124 delivered by BM-MSC derived exosomes on cell proliferation, epithelial mesenchymal transition, and chemotherapy sensitivity of pancreatic cancer cells

    Authors: , , , , , , - Aging 2020 cited by 63

  24. Depletion of high-content CD14+ cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Molecular Therapy — Methods & Clinical Development 2021 cited by 45